Skip to main content
Contact Us
Subscribe
e-Edition
Sign Up
Log In
Dashboard
Logout
My Account
Dashboard
Profile
Saved items
Logout
44°
Site search
Search
Menu
Subscribe
Home
News
Local News
Sports
Obituaries
e-Edition
Classifieds
Real Estate
Property For Rent
Cars & Vehicles
Jobs
Items For Sale
Pets
Auctions, Estate & Garage Sales
Services
Community
Personals
Place An Ad
Explore the Sheyenne
Archives
Best of 2024
Calendar Photos
Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Aptevo Therapeutics
Aptevo Therapeutics Announces New Preliminary Remission Data on Four Additional Patients Enrolled in On-going APVO436 Dose Expansion Phase 1b Trial for the Treatment of Acute Myeloid Leukemia
June 09, 2022
From
Aptevo Therapeutics
Via
AccessWire
Tickers
APVO
Aptevo Therapeutics Reports First Quarter 2022 Financial Results and Business Highlights
May 12, 2022
From
Aptevo Therapeutics
Via
AccessWire
Tickers
APVO
APVO442 Prostate Cancer Data Presented at the American Association for Cancer Research Annual Meeting
April 12, 2022
From
Aptevo Therapeutics
Via
AccessWire
Tickers
APVO
Aptevo Therapeutics Announces Monotherapy Patient Received a Transplant in APVO436 Expansion Trial for the Treatment of Acute Myeloid Leukemia
March 29, 2022
From
Aptevo Therapeutics
Via
AccessWire
Tickers
APVO
Aptevo Therapeutics Reports 2021 Financial Results and Provides Business Update
March 24, 2022
From
Aptevo Therapeutics
Via
AccessWire
Tickers
APVO
Aptevo Therapeutics Earns $10 Million Non-Dilutive Milestone Payment on Sales of RUXIENCE, Provides Company Update
February 09, 2022
From
Aptevo Therapeutics
Via
AccessWire
Tickers
APVO
Aptevo Therapeutics' Board Chairman, Fuad El-Hibri, Announces Retirement, Effective April 1, 2022
January 21, 2022
From
Aptevo Therapeutics
Via
AccessWire
Topics
Retirement
Exposures
Pension
Tickers
APVO
Alligator Bioscience & Aptevo Therapeutics Announce Co-Publication in Peer-Reviewed Journal, "Nature Communication"
December 15, 2021
From
Aptevo Therapeutics
Via
AccessWire
Tickers
APVO
Aptevo Therapeutics Reports First Complete Remission, Providing Clinical Update for Its Phase 1b Multi Center, Multi Cohort Expansion Trial in the Treatment of Acute Myeloid Leukemia
November 23, 2021
From
Aptevo Therapeutics
Via
AccessWire
Exposures
COVID-19
Tickers
APVO
Aptevo Therapeutics Announces the Presentation of Two Abstracts at the Upcoming American Society of Hematology Annual Meeting
November 15, 2021
From
Aptevo Therapeutics
Via
AccessWire
Exposures
COVID-19
Tickers
APVO
Aptevo Therapeutics Reports Third Quarter Financial Results With Business Highlights
November 12, 2021
From
Aptevo Therapeutics
Via
AccessWire
Exposures
COVID-19
Tickers
APVO
Alligator Bioscience and Aptevo Therapeutics Announce a Poster Presentation of ALG.APV-527 at SITC Annual Meeting 2021
November 11, 2021
From
Aptevo Therapeutics
Via
AccessWire
Exposures
COVID-19
Tickers
APVO
Aptevo Therapeutics Announces Preclinical Data for Bispecific Antibody APVO603 at the Society for Immunology in Cancer Annual Meeting
November 11, 2021
From
Aptevo Therapeutics
Via
AccessWire
Exposures
COVID-19
Tickers
APVO
Aptevo Therapeutics Presents Promising Clinical Data on Its Lead Leukemia Drug Candidate APVO436 at The Second Virtual Conference on Controversies in Leukemias, Euroleuk2021
October 27, 2021
From
Aptevo Therapeutics
Via
AccessWire
Exposures
COVID-19
Tickers
APVO
Aptevo Therapeutics Reports in the Refereed Medical Journal Cancers That the Risk of Cytokine Release Syndrome Is Low for Blood Cancer Patients Treated With Its Bispecific Antibody APVO436
October 26, 2021
From
Aptevo Therapeutics
Via
AccessWire
Exposures
COVID-19
Tickers
APVO
Aptevo Therapeutics Announces Publication of a Scientific Article in Peer-Reviewed Journal, Frontiers in Aging
September 28, 2021
From
Aptevo Therapeutics
Via
AccessWire
Exposures
COVID-19
Tickers
APVO
Aptevo Therapeutics Announces APVO436 Monotherapy is Active in Patients Who Have Relapsed Acute Myeloid Leukemia or Myelodysplastic Syndrome
August 17, 2021
From
Aptevo Therapeutics
Via
AccessWire
Exposures
COVID-19
Tickers
APVO
Aptevo Therapeutics Reports Second Quarter Financial Results with Business Highlights
August 12, 2021
From
Aptevo Therapeutics
Via
AccessWire
Exposures
COVID-19
Tickers
APVO
Aptevo Therapeutics' Chief Scientific Officer, Jane Gross, PhD, to Present at Upcoming Cambridge Health Institute PEGS Virtual Conference
July 16, 2021
From
Aptevo Therapeutics
Via
AccessWire
Exposures
COVID-19
Tickers
APVO
Aptevo Therapeutics' Scientists to Present At Virtual Cell Engager Summit
June 30, 2021
From
Aptevo Therapeutics
Via
AccessWire
Exposures
COVID-19
Aptevo Therapeutics Announces Inclusion in the Russell Microcap(R) Index
June 29, 2021
From
Aptevo Therapeutics
Via
AccessWire
Exposures
COVID-19
Lead
Tickers
APVO
Aptevo Therapeutics Announces Expansion Phase of Lead Anti-Leukemia Drug APVO436 in Adult Patients with Acute Myeloid Leukemia
May 27, 2021
From
Aptevo Therapeutics
Via
AccessWire
Exposures
COVID-19
Tickers
APVO
Aptevo Therapeutics Reports Positive Phase 1 Clinical Data for Its Lead Leukemia Drug Candidate APVO436 in Adults With Relapsed Acute Myeloid Leukemia
May 26, 2021
From
Aptevo Therapeutics
Via
AccessWire
Topics
Death
Intellectual Property
Exposures
COVID-19
Death
Intellectual Property
Tickers
APVO
Aptevo Therapeutics Reports First Quarter 2021 Financial Results
May 11, 2021
From
Aptevo Therapeutics
Via
AccessWire
Exposures
COVID-19
Tickers
APVO
Aptevo Therapeutics to Present at the American Association for Cancer Research Virtual Annual Meeting
April 09, 2021
From
Aptevo Therapeutics
Via
AccessWire
Exposures
COVID-19
Tickers
APVO
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.